USPTO serial 88028436
NOVELLUS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 10, 2020
- Examiner
- BRADLEY, EVELYN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NOVELLUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rachelle A. Dubow, Esq.
RACHELLE A. DUBOW, ESQ. MORGAN, LEWIS & BOCKIUS LLPONE FEDERAL STREETATTN: TMSUBOSTON, MA 02110Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering | ACTIVE | Oct 1, 2019 |
| 005 | Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease | ACTIVE | — |
| 009 | Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments | ACTIVE | Nov 8, 2019 |
| 042 | Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Factor Bioscience LLC
- Other trademarks owned by Factor Bioscience LLC
- Other trademarks owned by Factor Bioscience LLC
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named NOVELLUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 10, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 10, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 7, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 6, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 29, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Dec 29, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 18, 2019 | IUAF | USE AMENDMENT FILED | — |
| Dec 18, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 13, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 18, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 29, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 10, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 10, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 10, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 10, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 10, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 9, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 9, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 9, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 10, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 10, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 10, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 19, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 19, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 18, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 12, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 27, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 27, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 27, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 12, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 10, 2018 | NWAP | NEW APPLICATION ENTERED | — |